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Treatment of Acute Venous
Thromboembolism
Sashi Nair, MDa, Nina Garza, DO, MPHa, Matt George, MDb, Scott Kaatz, DO, MScc,*
INTRODUCTION AND EPIDEMIOLOGY
Acute venous thromboembolism (VTE) has an annual incidence rate of 1 to 2 per 1000
persons in the United States.1 Despite increasing efforts to prevent occurrence, rates
continue to increase in hospitalized patients across the United States.2 VTE also rep-
resents a significant source of health care expenditures—with cost estimated between
$14 billion and 27 billion annually.3 This article reviews the current evidence regarding
treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as
review updates in special populations (cancer, obesity, and renal disease).
PULMONARY EMBOLISM
Risk Stratification
PE has a wide spectrum of presentations and outcomes ranging from incidental imag-
ing findings to cardiovascular collapse, thus risk stratification of PE is essential.
Patients who are hemodynamically unstable (traditionally defined as a persistent
systolic blood pressure less than 90 mm/hg or requirement of vasopressors, with
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KEY POINTS
 Guidelines suggest using direct oral anticoagulants (DOAC) over traditional therapy for
low-molecular-weight heparin (LMWH) and warfarin for acute deep vein thrombosis
(DVT) and pulmonary embolism (PE) based on their safety profile.
 The best route, dose, or need for thrombolytic treatment of intermediate-risk PE is an
active area of research, and a definitive therapeutic approach is not currently established.
 Guidelines suggest against the routine use of thrombolytics in most patients with DVT.
 The use of DOACs in patients with cancer-associated DVT and PE is emerging, and guid-
ance is beginning to suggest their use instead of LMWH as first-line treatment.
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clinical or biochemical signs of hypoperfusion) are defined as those with high-risk or
massive PE.4 Hemodynamically stable patients require further stratification. The Pul-
monary Embolism Severity Index (PESI) score and the simplified (sPESI) score are risk
assessment models that have been incorporated into guidelines.5,6 Multiple online risk
calculators and mobile applications are available to facilitate application of these
scores. Patients who have an elevated risk based on PESI/sPESI are classified as in-
termediate risk. Intermediate risk patients are further stratified. Those with both right
heart strain on imaging, and positive troponins are classified as intermediate-high
risk, those with either right heart strain or troponins are intermediate low risk. Low
risk patients are defined by a low PESI/sPESI score. Patients who would otherwise
have been classified as low risk by sPESI or PESI, but are found to have evidence
of right heart strain or troponin elevation are known to have increased mortality and
should be treated as intermediate risk.4,7
High-risk/massive pulmonary embolism
Initial stabilization of the patient with acute high-risk PE is based on lessons from pa-
tients with acute right heart failure.8,9 This may include an intravenous (IV) fluid bolus of
no more than 500 cc, as excess preload on an overdistended ventricle may worsen
shock. Vasopressors may be required to maintain systemic perfusion with norepi-
nephrine or dobutamine (preferred). Supplemental oxygen progressing to low tidal vol-
ume, low peak pressure ventilation can be used to support oxygenation as patients
with PE are particularly sensitive to increased intrathoracic pressure. Case series
have demonstrated the role of venoarterial extracorporeal membrane oxygenation
as a bridge to definitive therapy, which may entail thrombolysis, embolectomy, or
catheter-directed methods.10
The cornerstone of management in high-risk or massive PE is reperfusion. Systemic
thrombolysis improves mortality in patients with high-risk PE albeit with an increased
incidence of major bleeding and approximately 2% rate of intracranial hemorrhage
(ICH).11 In patients who have absolute contraindications to thrombolysis, surgical
thrombectomy is a viable alternative with similar mortality rates.12 In patients who
are not candidates for systemic thrombolysis or surgical embolectomy, or in patients
with failed thrombolysis, catheter-based therapies (Table 1) can be considered.
Intermediate risk/submassive pulmonary embolism
The role of thrombolysis in patients with intermediate-risk PE is not clear. The PEITHO
trial randomized 1005 participants to receive placebo or weight-based (30–50mg) ten-
ecteplase in addition to standard of care. Results provided evidence that thrombolysis
may decrease the combined endpoint of mortality or escalation of care at the cost of
increased rate of ICH in patients with intermediate-risk PE.18 There was no statistically
significant difference in mortality, but there was a significant decrease in the rate of
hemodynamic decompensation (1.6% vs 5%, odds ratio [OR] 0.3, P 5 .002). Throm-
bolytic treatment was associated with a significant increase in stroke (2.4% vs
0.2%, OR 12.1, P 5 .003) and extracranial bleed (6.3% vs 1.2%, OR 5.55, P<.001).
Subsequent meta-analyses have yielded a significant mortality benefit in the
intermediate-risk PE population and a signal toward less bleeding for patients
younger than 65 years who receive thrombolysis compared with patients older than
65 years who receive thrombolysis.19,20 However, the routine use of systemic throm-
bolysis in intermediate-high–risk patients has not been supported by either the Euro-
pean Society of Cardiology 2019 or American College of Chest Physicians 2016
guidelines.4,21 Although available evidence for patients with intermediate-high–risk
PE is unclear, patients should be closely monitored regardless of treatment choice,
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as the median time to death or decompensation was 1.8 days in the placebo group in
the PETHIOS trial.18
Controversy also exists regarding the dose of tissue plasminogen activator (tPA),
with full dose considered to be 100 mg of alteplase given over 2 hours. The MOPPET
trial enrolled 121 patients with “moderate” PE (determined by clot burden of greater
than 70% involvement of thrombus in 2 or more lobar or the main pulmonary arteries)
and randomized them to receive either 0.5 mg/kg (max 50 mg) or placebo in addition
to standard of care. There was a statistically significant decrease in the rate of pul-
monary hypertension and recurrent PE at 28 months (16% vs 63%, P<.001), as well
as hospital length of stay (2.2 days vs 4.9 days, P<.001) but not in mortality (1.6% vs
5%, P 5 .3).22However, contrary evidence has emerged comparing full- versus
reduced-dose tPA, showing no clear mortality or bleeding risk benefit with a reduced
dose and demonstrating increased need for escalation of care.23
An alternative method of reduced-dose thrombolysis is intrapulmonary arterial
administration with catheter-based therapies. Numerous devices are becoming
available, consisting of an intrapulmonary catheter with or without the addition of
energy-assisted thrombolysis or thrombectomy (see Table 1). Various studies have
investigated these techniques; however, the role of catheter-based therapies for inter-
mediate-high–risk PE is still unclear. Available evidence has shown favorable reduc-
tions in right ventricular size and pulmonary arterial pressure as surrogates for
efficacy and mortality with minimal bleeding complications and rates of intracranial
hemorrhage of less than 1%. To date no trials have demonstrated a mortality
benefit.13–17 Given the numerous therapeutic options and modalities available, many
hospitals have built Pulmonary Embolism Response Teams (PERT) to provide
Table 1
Catheter-based reperfusion strategies
Type Principle Selected Examples Selected Studies
Catheter-
directed lysis
Direct, local pulmonary
arterial administration of
thrombolytics can potentially
reduce the required dose,
increase efficacy, and improve
safety
 Unifuse Catheter
system
 Cragg-McNamara
system
 PERFECT13
Ultrasound-
assisted
thrombolysis
Local ultrasonic energy may
facilitate penetration of
thrombolysis into thrombi.
Typically use slow infusion
of 1-2 mg/min of tPA and 12–24-
h dwell time of catheter in the
pulmonary artery
 EKOSonic  ULTIMA14
 SEATTLE II15
Mechanical-
assisted
catheters
Use of mechanical disruption,
suction, or rheolytic effects to
disrupt thrombi can be used
without thrombolysis
in patients who have
contraindications
 FlowTriever—
mechanical
disruption
 Penumbra-indigo—
rheolytic destruction
 AngioVac-Suction
thrombectomy
 FLARE16
 EXTRACT-PE17
(ongoing)
Unifuse Catheter system (AngioDynamics, Latham NY), Cragg-McNamara system (Medtronic, Min-
neapolis MN), EKOSonic (Boston Scientific, Marlborough MA), FlowTriever (Inari Medical, Irvine
CA), Penumbra-indigo (Penumbra Inc, Alameda CA), AngioVac (AngioDynamics, Latham NY).
Abbreviation: tPA, tissue plasminogen activator.
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management recommendations in these complex patients. The European Society of
Cardiology has given a class IIa recommendation for consultation with a PERT
team, although questions remain on optimal size, composition, and funding.4
There is no established role of thrombolysis or catheter-directed therapy for
the intermediate-low–risk PE, hence the mainstay of therapy remains systemic
anticoagulation.4,21
Low-risk pulmonary embolism
Patients with low-risk PE who have no other reason for hospitalization or additional
barriers to treatment adherence can be managed at home with no increase immor-
tality. The Outpatient Treatment of Pulmonary Embolism trial randomized 344 patients
with low-risk PE to inpatient or outpatient treatment and demonstrated noninferiority
of outpatient therapy.24 The Hestia criteria have been developed to standardize the
selection of these patients (Box 1).25 If a patient lacks any of the Hestia criteria they
may be an appropriate candidate for early discharge and home treatment.
Controversy still exists regarding the management of isolated small subsegmental
PE. Interobserver variability can be as high as 50%, and in the absence of proximal
DVT or risk factors, patients with isolated subsegmental PE who did not receive anti-
coagulation have a VTE recurrence rate and mortality similar to those who were anti-
coagulated.26–28 Conservative management and close follow-up may be a reasonable
treatment plan if there is no DVT.
DEEP VEIN THROMBOSIS
Distal Deep Vein Thrombosis
Anticoagulation for isolated distal calf vein thrombosis is controversial because the
risk of PE is low; however, extention to the popliteal vein and hence a proximal DVT
is of concern. The American College of Chest Physicians (ACCP) guidelines suggest
either no anticoagulation plus mandatory Doppler surveillance for extention for more
than 2 weeks or anticoagulation in patients with risk of extention.21
Box 1
The Hestia criteria for early discharge and home treatment of pulmonary embolism
 Hemodynamically unstable
 Thrombolysis or embolectomy needed
 Active bleeding or high risk for bleeding
 PE diagnosed while on anticoagulation
 Severe liver impairment
 Renal disease with creatinine clearance less than 30 mL/min
 Pregnancy
 Documented history of heparin-induced thrombocytopenia
 Supplemental oxygen required to maintain SaO2 greater than 90% for more than 24 hours
 Severe pain needing IV pain medication required for more than 24 hours
 Medical or social reason for admission more than 24 hours
Adapted from Zondag W, Mos IC, Creemers-Schild D, et al. Outpatient treatment in patients
with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011;9(8):1501; with
permission.
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The CACTUS trial was reported after the publication of the ACCP guidelines and
was terminated early because study drug expired and only half of the planned number
of patients was enrolled. Two hundred fifty-nine outpatients with calf vein thrombosis
and no history of cancer or previous DVT were randomized to low-molecular-weight
heparin (LMWH) or placebo. There was no statistical difference in the composite
outcome of extention to proximal veins, contralateral DVT, or PE, and there was
more bleeding with LMWH versus placebo (4% vs 0%, 95% confidence interval
0.4–9.2).29 This underpowered trial suggests more harm than benefit in treating low-
risk, isolated calf vein thrombosis.
Catheter-Directed Thrombolysis for Acute Proximal Deep Vein Thrombosis
Thrombolysis, either systemic or catheter–based, using a variety of techniques has been
shown to improve vein patency for treatment of DVT with the hope of decreasing post-
thrombotic syndrome. However, ACCP guidelines suggest anticoagulant therapy alone
over catheter-directed thrombolysis.21ACochranesystematic reviewof 1103 randomized
patients in 17 trials found thrombolysis increased vein patency and reduced postthrom-
botic syndrome. However, this review did not include 692 patients in the ATTRACT trial.30
The ATTRACT trial randomized patients with acute proximal DVT to pharmacome-
chanical thrombolysis with tPA and thrombus aspiration or maceration with or without
stenting plus anticoagulation versus anticoagulation alone with a primary outcome of
postthrombotic syndrome between 6 and 24 months.31 Pharmacomechanical throm-
bolysis showed no efficacy in the primary outcome (47% vs 48%), a trend in improve-
ment in moderate-to-severe postthrombotic syndrome (18% vs 24%, P 5 .04 [<0.01
considered significant for multiple secondary outcomes]) and more major bleeding in
the first 10 days (1.7% vs 0.3%, P 5 .03), but no difference in bleeding at 24-month
follow-up. This trial indicates no long-term benefit and short-term harm with pharma-
comechanical thrombolysis.
The ACCP guidelines suggest anticoagulation over thrombolysis for upper extremity
DVT.21 Candidates likely to benefit would have thrombus in most of the subclavian and
axillary veins, symptoms of less than 14 days, good functional status, and low risk of
bleeding.
Compression Stockings to Prevent Postthrombotic Syndrome
Postthrombotic syndrome can affect up to half of patients with proximal DVT, and use
of compression stockings is thought to prevent venous dilatation and further valve
damage. ACCP guidelines suggest not using these based on the SOX trial, which is
the largest trial performed to date.21,32 The SOX trial randomized 806 patients with first
symptomatic proximal DVT to 30 to 40 mm Hg graduated elastic compression stock-
ing or placebo stockings with less than 5 mm Hg compression. Primary outcome was
development of postthrombotic syndrome at 2 years. There was no difference be-
tween active and placebo stocking groups using the specific Ginsberg scale (14.2%
vs 12.7%) or the sensitive Villalta scale (52.6% vs 52.3%). A subsequent meta-
analysis of 5 randomized trials, with the SOX trial representing more than half the pa-
tients, shows a 38% relative reduction in postthrombotic syndrome, although there
was large statistical heterogeneity (I2 5 80%).33
VENOUS THROMBOEMBOLISM TREATMENT
Initial Anticoagulation
Initial anticoagulation (or acute anticoagulation) refers to anticoagulation choice at
time of diagnosis. ACCP guidelines suggest DOACs over warfarin, and studies have
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demonstrated that DOACs have equal efficacy and improved safety.21 The dosing of
these various agents is reviewed in Table 2.
Vitamin K Antagonists
The first trial in 1960 that compared anticoagulant therapy with no anticoagulant
therapy in patients with symptomatic DVT or PE suggested that 1.5 days of heparin
and 14 days of vitamin K antagonist (VKA) therapy markedly reduced recurrent
PE and mortality in patients with acute PE.41 A 1992 randomized trial compared
continuous intravenous heparin plus VKA versus VKA alone and was terminated
early due to excess of symptomatic events in the VKA alone group.42 Therefore,
parenteral anticoagulation must be continued for at least 5 days and an Interna-
tional Normalized Ratio (INR) above 2 for 2 consecutive days.43 However, ACCP
does comment that if the INR exceeds the therapeutic range prematurely, it is
acceptable to stop parenteral therapy before the patient has received 5 days of
treatment.44,45
Table 2
Anticoagulation dosing for venous thromboembolsim
Anticoagulant Initial Dose and Length Maintenance Dose
Unfractionated
Heparin34
 Weight Based: 80 units/kg
bolus, then 18 units/kg/
h (preferred)
Adjust infusion rate to
maintain
target laboratory values
based
on institutional protocol to
maintain therapeutic aPTT
1.5–2.5 times the control
Low-Molecular-
Weight
Heparin
(Enoxaparin)35
 1 mg/kg twice daily
(preferred)
 1.5 mg/kg QD can be used in
nonobese patients
 CrCl <30 mL/min: reduce to
1 mg/kg once daily
Same
Fondaparinux36  5 mg QD (<50 kg)
 7.5 mg QD (50–100 kg)
 10 mg QD (>100 kg)
Same
Apixaban37  10 mg BID first 7 d
 CrCl 30 mL/min: has not
been studied
5 mg BID
Dabigatran38  150 mg twice daily (after
initial 5–10 d of parenteral
anticoagulation)
 CrCl 30 mL/min: has not
been studied
Same
Rivaroxaban39  15 mg BID for the first 3 wk
 CrCl <30 mL/min: avoid use
20 mg QD
Edoxaban40  60 mg once daily >60 kg
 30 mg once daily <60 kg or
CrCl 15–50 mL/min (after
initial 5–10 d of parenteral
anticoagulation)
Same
Abbreviation: aPTT, activated partial thromboplastin time; CrCl, creatinine clearance.
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Heparin, Low-Molecular-Weight Heparin, or Fondaparinux
ACCP guidelines suggest LMWH or fondaparinux over intravenous or subcutaneous
unfractionated heparin (UFH).44 A 2017 Cochrane meta-analysis of 29 randomized
controlled trialscomparing twicedailyLMWHwithUFH inpatientswithacuteVTEdemon-
strated recurrence in 3.6%withLMWHversus5.3%withUFH (OR0.72P5 .001) andma-
jor bleeding rates of 1.1% LMWH versus 1.9% UFH (OR 0.58 P5 .02).46,47
There are subsets of patients in whom IV UFH should still be the initial anticoagulant.
Patients with renal failure creatinine clearance (CrCl) less than 30 mL/min have relative
contraindications to LMWH, fondaparinux, and DOACs. Also, those who are hemody-
namically unstable from massive PE and those who may need urgent discontinuation
of anticoagulation should also be treated with IV UFH.4 A weight-based dosing nomo-
gram protocol is recommended over a non–weight-based protocol for IV UFH. A
higher percentage of patients randomized to weight-adjusted dosing achieve a ther-
apeutic activated partial thromboplastin time (aPTT) within 24 hours (97% vs 77%)
without an increase in major bleeding.34 The efficacy of IV UFH depends on achieving
a critical therapeutic level within 24 hours of initiation, which is target aPTT ratio of 1.5
to 2.5 times control. A pooled analysis of 3 randomized trials showed an increased risk
of recurrent VTE when a therapeutic aPTT was not achieved within 24 hours (23% vs
4%, P 5 .02).48 Fondaparinux has been found to be comparable to LMWH for acute
VTE treatment in the MATISSE trial with no difference in recurrent VTE, major bleeding,
or mortality.49 It also has the benefit of being able to be used in patients with history of
heparin-induced thrombocytopenia.
Direct Oral Anticoagulants
The ACCP antithrombotic guidelines give a grade 2B suggestion for a DOAC over VKA
therapy.21 This suggestion is based on less bleeding with DOACs and greater conve-
nience for patients and health care providers. The DOAC trials are summarized in
Table 3.
To mitigate the high recurrence rate in the first several weeks of treatment, 2 different
approaches were taken by trial investigators. Dabigatran and edoxaban were studied
with at least 5 days of lead in (not overlap) with parenteral anticoagulation before DOAC
initiation to help mitigate the high recurrence rate in the first week or so of therapy. Dabi-
gatran and edoxaban require at least 5 days of parenteral anticoagulation with unfractio-
nated heparin, LMWH, or fondaparinux and then parenteral anticoagulation is stopped
and they are started.50,51,55 Rivaroxaban was studied with a 50% increase of the daily
dose for 3 weeks, whereas the apixaban trial used a 2-fold increase for 1 week.52–54
Long-Term Anticoagulation
Long-term anticoagulation refers to treatment during the initial 3 months. At 3 months
the decision is made on whether to extend anticoagulation based on risk of recurrence
and bleeding (Table 4).
A 2014 review of 6 trials including 27,023 patients with VTE compared DOACs with
VKAs; recurrent VTE occurred in 2.0% of DOAC recipients versus 2.2% in VKA recip-
ients. Treatment with a DOAC significantly reduced the risk of major bleeding (risk ratio
0.61 P 5 .002) as well as intracranial bleeding, fatal bleeding, and clinically relevant
nonmajor bleeding.56
Extended Anticoagulation
Extended anticoagulation refers to treating indefinitely past 3-month standard long-term
treatment. This decision must weigh the risk of VTE recurrence versus bleeding. Several
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scoring systems have been developed to assist in estimating VTE recurrence. The Men
and HERDOO2 rule (hyperpigmentation, edema, or redness in either leg; D-dimer level
250 mg/L; obesity with body mass index 30; or Older age 65 years) estimated that
women with an unprovoked VTE who have 0 of the criteria are low risk for recurrent VTE
Table 4
American College of Chest Physicians guideline anticoagulation length for proximal deep vein
thrombosis or pulmonary embolism
Type of VTE Bleeding Risk Suggested Length Grade of Evidence
Provoked by surgery All 3 mo 1B
Provoked by a nonsurgical
transient risk factor
Low/Moderate 3 mo 2B
High 3 mo 1B
Unprovoked first VTE Low Extended (no stop date) 2B
Unprovoked first VTE High 3 mo 1B
Unprovoked second VTE Low Extended (no stop date) 1B
Unprovoked second VTE Moderate Extended (no stop date) 2B
Unprovoked second VTE High 3 mo 2B
Active cancer Low/Moderate Extended (no stop date) 1B
Active cancer High 3 mo 2B
Data from Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guide-
line and Expert Panel Report. Chest 2016;149(2):315-352.
Table 3
Direct oral anticoagulant trials
Anticoagulant Trial Year
Recurrent
VTE, DOAC
vs Control Safety Outcomes
Dabigatran RE-COVER50 2009 Noninferiority
2.4% vs 2.1%
No significant difference in major
bleeding
Significant reduction in any bleeding
in dabigatran (16.1% vs 21.9%)
Dabigatran RE-COVER II51 2014 Noninferiority
2.3% vs 2.2%
No significant difference in major
bleeding
Significantly less any bleeding in
dabigatran (15.6% vs 22.1%)
Rivaroxaban EINSTEIN-
DVT52
2010 Noninferiority
2.1% vs 3.0%
No significant difference in first major
or clinically relevant nonmajor
bleeding
Rivaroxaban EINSTEIN-PE53 2012 Noninferiority
2.1% vs 1.8%
No significant difference in first major/
clinically relevant nonmajor
bleeding
Significant decrease in major bleeding
(1.1% vs 2.2%)
Apixaban AMPLIFY54 2013 Noninferiority
2.3% vs 2.7%
Significantly less major bleeding (0.6%
vs1.8%)
Significantly less clinically relevant
bleeding (3.8% vs 8.0%)
Edoxaban Hokusai-VTE55 2013 Noninferiority
3.2% vs 3.5%
No significant difference in major
bleeding
Significantly less clinically relevant
bleeding (8.5% vs10.3%)
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and stopping anticoagulation can be considered.57 The DASH score uses risk factors of
D-dimer, age, sex, and hormonal therapy for patient with an unprovoked VTE. A score
less than or equal to 1 has a low annualized recurrence risk of 3.1%; anticoagulation
may be able to be discontinued in these patients.58 ACCP guidelines use 5 risk factors
(Table 5) to guide the decision for extended anticoagulation.
Unlike atrial fibrillation in which the HAS-BLED score has been extensively vali-
dated, there are few robust bleeding risk assessment models for VTE. The RIETE
score, which uses age greater than 75 years, recent bleeding, cancer, creatinine levels
greater than 1.2 mg/dL, anemia, or pulmonary embolism, may be used to estimate
bleeding risk.59 The ACCP guidelines use bleeding risk factors (Table 6) to guide their
recommendations for extended anticoagulation.
There have been multiple trials to evaluate extended anticoagulation, including
anticoagulants versus placebo, anticoagulants versus aspirin, and aspirin versus pla-
cebo. Extended treatment with lower dose warfarin (INR 1.5–2.0), aspirin, or prophy-
lactic dose DOAC have also been studied to mitigate bleeding, and selected trials are
summarized (Table 7).
Usual dose warfarin (INR 2–3) is more effective and as safe as lower dose; prophy-
lactic dose apixaban has less recurrence and no significant increase in major bleeding
compared with placebo, and prophylactic dose rivaroxaban is more efficacious and as
safe as aspirin. The use of lower prophylactic dose DOACs with their respective lower
bleeding risk questions the traditional recurrent VTE threshold and therefore we
recommend considering extended treatment of most patients.
SPECIAL POPULATIONS
Malignancy
Active malignancy represents a significant risk factor for VTE; the risk of proximal DVT
or PE is 4- to 7-fold higher in patients with cancer compared with those without.68 Initi-
ation of anticoagulation further represents a challenge in this patient population, as
they are significantly more likely to experience bleeding complications as well as
VTE recurrence compared with the general population. Although guidelines have pre-
viously emphasized LMWH as first-line treatment, there is increasing evidence and
acceptance for use of DOACs in the treatment of cancer-associated VTE. The Hokusai
VTE Cancer study found edoxaban had similar net clinical benefit of recurrence and
major bleeding as dalteparin with numerically less recurrence and more major
bleeding with edoxaban.69 Similarly, in the SELECT-D trial, rivaroxaban had a similar
numeric trend of less recurrence and more bleeding with rivaroxaban compared with
Table 5
American College of Chest Physicians’ estimated venous thromboembolism recurrence risk
Risk Factor Recurrence Risk
Surgery 3% at 5 y
Transient nonsurgical (estrogen therapy,
pregnancy, leg injury, flight of >8 h)
15% at 5 y
Unprovoked 30% at 5 y
Cancer 15% annual (not calculated at 5 y due to
higher mortality)
Second unprovoked VTE 45% at 5 y
Data from Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guide-
line and Expert Panel Report. Chest 2016;149(2):315-352.
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dalteparin.70 Both studies reported increased bleeding, mainly in patients with intact
luminal gastrointestinal malignancies. More recently, the ADAM VTE trial studied the
use of apixaban compared with dalteparin in patients with cancer and found lower
rates of recurrent VTE with no increase in bleeding complications.71 Given these find-
ings, and in view of ISTH and NCCN guidelines, we recommend consideration of either
of these agents for the treatment of cancer-related VTE, with very careful consider-
ation of bleeding risk in those with gastroesophageal malignancy.72–74
Obesity
The use of DOACs in morbid obese patients (defined as a body mass index
[BMI] >40 kg/m2) remains controversial due to a paucity of clinical data in this popu-
lation. To date, there has been no randomized clinical trial comparing vitamin K antag-
onist and DOACs dedicated to patients with BMI greater than 40 kg/m2 for the
treatment of acute VTE. Pharmacokinetic studies have indicated the challenge in using
DOACs due to higher volume of distribution and lower mean peak concentration in pa-
tients weighing greater than 120 kg. Because of these obstacles, clinical guidance fa-
vors VKA over DOACs for patients with a BMI greater than 40 kg/m2 or 120 kg or
greater than 35 kg/m2 or 120 kg.75,76 In contrast, there have been retrospective
studies investigating clinical outcomes with use of rivaroxaban, which found no in-
crease in recurrent VTE or bleeding.77 Further, the Dresden NOAC registry found
elevated BMI is associated with a decrease in adverse events with use of DOACs,
the so-called obesity paradox.78
Given the lack of data to support definitive recommendations in patient with acute
VTE and BMI greater than 35 to 40 kg/m2, it is suggested to use vitamin K antagonists
in this population. In the appropriate clinical scenario, DOACs can be considered and
management guided by DOAC levels according to ISTH guidance—anti-FXa levels for
edoxaban, rivaroxaban, or apixaban or dilute thrombin time for dabigatran, although
they are not readily available. Mass spectrometry drug levels can alternatively be
used for all DOACs.75
Renal Failure
Chronic kidney disease represents an independent risk factor not only for VTE occur-
rence but also for bleeding complications during treatment. Patients with CrCl less
Table 6
American College of Chest Physicians’ bleeding risk categories
Age >65 y Diabetes
Age >75 y Anemia
Previous bleeding Antiplatelet therapy
Cancer Poor anticoagulant control
Metastatic cancer Comorbidity and reduced functional capacity
Renal failure Recent surgery
Liver failure Frequent falls
Thrombocytopenia Alcohol abuse
Previous stroke Nonsteroidal antiinflammatory drug
Risk Factors
Low: 0 risk factors; Moderate: 1 risk factor; High: 2 risk factors
Adapted from Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST
Guideline and Expert Panel Report. Chest 2016;149(2):329; with permission.
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Table 7
Extended anticoagulation trials
Trial Year Anticoagulation Control Recurrent VTE Efficacy Safety Outcomes
Kearon Seminal
Study60
1999 Warfarin
(additional
24 mo)
Placebo Significantly reduced, 1.3% vs 27.4%
per 100 person-years
No significant difference in major bleeding
PREVENT61 2003 Low-intensity
Warfarin
(INR 1.5–1.9)
Placebo Significantly reduced, 2.6 vs 7.2 per
100 person-years
No significant difference in major bleeding
ELATE62 2003 Low-intensity
Warfarin
(INR 1.5–1.9)
Standard
Warfarin
(INR 2–3)
Significantly increased, 1.9 vs 0.7 per
100 person-years
No significant difference in any or major bleeding
EINSTEIN
CHOICE63
2017 Rivaroxaban
20 mg
Aspirin Significantly reduced, 1.5% vs 4.4% No significant difference clinically relevant or major
bleeding
2017 Rivaroxaban
10 mg
Aspirin Significantly reduced, 1.2% vs 4.4% No significant difference in clinically relevant or major
bleeding
AMPLIFY-EXT64 2013 Apixaban 2.5 mg Placebo Significantly reduced, 1.7% vs 8.8 No significant difference in major bleeding or clinically
relevant nonmajor bleeding
2013 Apixaban 5 mg Placebo Significantly reduced, 1.7% vs 8.8 No significant difference in major bleeding
Increased clinically relevant nonmajor bleeding (1.82 RR)
RE-MEDY65 2013 Dabigatran Warfarin Noninferiority, 1.8% vs 1.3% No significant difference in major bleeding
Significant decreased major or clinically relevant
bleeding, 5.6% vs10.2%
RE-SONATE65 2013 Dabigatran Placebo Significantly reduced, 0.4% vs 5.6% Significantly increased major or clinically relevant
bleeding, 5.3% vs1.8%
ASPIRE66 2012 Aspirin Placebo No significant difference No significant difference in major or clinically relevant
nonmajor bleeding
WARFASA67 2012 Aspirin Placebo Significantly reduced, 6.6% vs 11.2% No significant difference in major or clinically relevant
nonmajor bleeding
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than 30 mL/min, calculated with the Cockroff-Gualt equation using actual body
weight, were excluded from trials that studied DOACs in the treatment of acute
VTE.79 Given the lack of data in this patient population, vitamin K antagonists are likely
preferred for the treatment of VTE in patients with a CrCl less than 30 mL/min.
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